Left: Founder Dr Jane Cardosa
Center: Dr Uwe Schlokat
Right: Michelle Gan

Interview with Dr Uwe Schlokat, CEO of Sentinext Therapeutics

Emily Event News Leave a Comment

Founded in 2008, Sentinext is a Malaysian biotech company which focuses on building innovative vaccines to protect Asia populations against infectious viral diseases. Using its proprietary Virus-like particle (VLP technology), Sentinext’s trademark project is to build vaccines for Hand foot mouth disease (HFMD), a highly prevalence infection among children in Asia. We have had the opportunity to interact with its CEO …

Capture 2

Maximizing injectables production: Enabling consistent supply

mildred Uncategorised Leave a Comment

One of the most significant trends today in our industry is the enormous growth of the injectable market. Injectables are becoming the single largest driver of the pharma/biotech market and offer tremendous opportunity. However, bringing an injectable to market is no small feat. Staying competitive, once in the market, can be just as challenging. Market and regulatory requirements regarding safety …

Capture 1

Meeting the inherent challenges of complex drug substances

mildred Uncategorised Leave a Comment

Realizing the full potential of a novel injectable drug compound is no small task. In the months and years that lead from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can slow development to a halt, often at key stages. A careful, systematic approach to identifying where and why these roadblocks …

Image taken from http://knowledge.wharton.upenn.edu/article/precision-medicine-new-paradigms-risks-opportunities/

Moving towards genomics driven precision medicine in Asia

Emily Event News Leave a Comment

Emerging technologies are disrupting every industry, with no exception to  biomedical industry in Asia. Early stage biotech companies including Strand Lifesciences are tapping onto this latest trend to provide innovative tools and strategies to improve how stakeholders work in the industry. Vijay Chandru, Executive Chairman of Strand Lifescience joined us at the 14th BioPharma India, Mumbai on 15-16 November 2016. In case …

Image taken from http://www.genomeasia100k.com/

Sustaining innovation-based biotech in the home of generics

Emily Event News Leave a Comment

India is probably one of the world’s most successful generics markets. Despite all the scandals related to quality of the generics drugs supplied to developed market, the country still remains the home of low cost, high quality generics production. We interviewed Dr C.N. Ramchand, founder of several innovative companies including Saksin Lifesciences and MagGenome to seek his rationale of going …

Image taken from http://www.cfr.org/china/chinese-pharma-global-health-game-changer/p36365

Regaining the confidence of Chinese biomanufacturing industry

Emily Event News Leave a Comment

Similar to other developing countries, the quality of Chinese bioproduction is often questioned by international markets due to various outbreak of scandals related to breach of quality protocols in production process. We invited Dr Amy Que, Vice President of Quality Control of Innovent Biologics, one of the leading innovation-driven biotech companies emphasizing on quality production to speak at the 10th BioPharma …

Professor David Virshup (left) and Professor Alex Matter are the lead scientists working on a drug that holds out much hope for cancer patients- Image taken from Straits times

Interview with Dr Alex Matter, CEO Of Experimental Therapeutics Center A*STAR and an oncology expert

Emily Event News Leave a Comment

Dr Alex Matter is no stranger oncology experts. Formerly the Global Head of Oncology Research at Novartis, he also played an important role in the success of several anticancer drugs, including Gleevec/Glivec® and more recently, Tasigna® and several other anticancer drugs as well as one HIV protease inhibitor (Reyataz®) that is marketed by another company. Ahead of Dr Matter joining us …

Image taken from http://bridgeable.com/wp-content/uploads/940500_3_Segment-Patients-620x287.png

Medical affairs in India and South Asia

Emily Event News Leave a Comment

Medical affairs is an increasingly important role in Asia’s pharmaceutical industry. Beside serving as the connecting point between stakeholders, this function serves as a crucial role to improve confidence of drugs and stakeholders opinion of the pharma companies. Working closely with patients, physicians, regulators and payers, close professional communications and evidence presentations are what is needed in a high performing …

What are the differences in safety regulations when comparing Europe and Chinese industry?

 Image taken from Roche website

Drawing parallels between EU and Chinese safety regulations

Emily Event News Leave a Comment

Needless to say, everyone within the industry is well aware of Asia’s potential in science and technology. But to understand more about the international perspective on expanding their business to Asia, we invite speakers from Asia and international market to provide a comprehensive overview of the global industry at BioPharma Asia Convention 2017, Singapore. One of the early confirmed international speakers …

Imugene

Imugene’s therapeutic vaccines in treating gastric cancer

Emily Event News Leave a Comment

Gastric cancer is one of the top causes of death in Asia. More than 50% of gastric cancer cases happen in East Asia, and as the 3rd most common cancer after breast and lung cancer, it is important to develop prevention method to prevent and cure this disease. Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. …